Summary Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented. We evaluated the efficacy of mitotane treatment of 96 patients with adrenocortical carcinoma followed up in our department between 1959 and 1992. Complete tumour resection was the goal of the initial treatment. Mitotane treatment was classified according to serum trough concentrations on maintenance therapy: low (<14mgl-') or high (>14mg1-'). Total tumour resection was feasible in 47 patients (49%), and subtotal resection was performed in 37 patients (39%). Patients who underwent total tumour resection survived significantly longer than those who did not (P<0.001). Adjuvant mitotane therapy (n = 11) did not influence survival after total resection. Sixty-two patients were given mitotane treatment at some time during their illness, only 30 of whom reached high maintenance serum levels. Mitotane treatment with high serum levels had an independently favourable influence on patient survival, using univariate (P<0.01) and multivariate analysis (P = 0.01). Mitotane treatment resulting in low serum levels was tantamount to not giving mitotane at all. We conclude that mitotane treatment in adrenocortical carcinoma is effective only when high serum levels can be achieved.
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Carcinoma of the adrenal cortex carries a poor prognosis (Macfarlane, 1958; Hutter & Kayhoe, 1966a; Venkatesh et al., 1989; Luton et al., 1990) . According to recently reported clinical studies, only 20-25% of patients survive for more than 5 years after the diagnosis is made (Venkatesh et al., 1989; Luton et al., 1990) . Early diagnosis and radical surgery offer the best hope for long-term survival. However, the diagnosis is frequently delayed and often only made at an advanced stage because of its rarity and the deep retroperitoneal localisation of the adrenal glands.
Another important factor contributing to the prognosis is the poor response to chemotherapeutic agents. Mitotane (o,p'-DDD) is considered to be the drug of choice for patients with inoperable, recurrent and metastatic disease (Samaan & Hickey, 1987) . Increase in survival (Hutter & Kayhoe, 1966b; Lubitz et al., 1973; Venkatesh et al., 1989) and even long-term remission and cure of adrenocortical cancer (Becker & Schumacher, 1975; Jarabak & Rice, 1981) have been attributed to mitotane. Unfortunately, because of the rarity of the tumour, no randomised or controlled studies have been performed to assess mitotane's effect on patients' survival in adrenocortical carcinoma. However, a recently completed retrospective (multivariate) analysis of 105 patients with carcinoma of the adrenal cortex failed to document improved survival due to mitotane therapy (Luton et al., 1990) . In a retrospective study conducted in our hospital (van Slooten et al., 1984) (Mathews & Farewell, 1985) .
Results
Clinical characteristics (Table I (Figure 2 ). Five year survival after total resection was 49%, and after subtotal resection only 9%. Rupture of the tumour capsule during resection did not significantly influence survival (P= 0.38). All patients with inoperable disease died within 18 months of diagnosis.
Mitotane Sixty-two patients received mitotane at some time during their illness between 1965 and 1991. The five patients diagnosed between 1959 and 1965 and not treated with mitotane had local disease. Maintenance therapy serum levels were found to be high (range 14-50 mg I-', 74% between 14 and 25mgl1) in 30 patients and low (range 4-13mgl', 84% between 7 and 11 mg -') in 32 others. The mitotane formulations from the two manufacturers were bioequivalent. No differences between serum levels reached depending on the brand used were observed.
Forty of the 62 patients who were treated with mitotane at some time during their illness received the drug early in the course of their illness. Twenty-nine of these 40 patients had measurable tumour size because they were not operated upon (five patients) or because they only underwent a subtotal resection (24 patients). A tumour response was only seen in six patients having high maintenance mitotane serum levels (Table II) again only observed in patients with a high maintenance mitotane level (n = 9) (Table III) (P <0.001, chi-square test). Five of these patients had a complete remission lasting for 2-120 months at the time of reporting.
Mitotane therapy was given to 11 patients after apparently complete tumour resection. Six of these patients reached mitotane serum levels over 14 mg 1-'. Median survival of the 11 patients treated with adjuvant mitotane was 51 months. The median survival of the patients with complete tumour resection without adjuvant therapy was 61 months. The differences in survival and disease-free survival between these groups of patients were not significant.
Mitotane side-effects The main side-effects of mitotane were anorexia, nausea, vomiting, diarrhoea and CNS toxicity. Mitotane treatment had to be discontinued in ten patients because of side-effects. These were anorexia and nausea in eight patients and neuropsychiatric symptoms in two patients. Nine of the ten patients stopping treatment because of side-effects never achieved high mitotane serum levels. Gastrointestinal manifestations were present early in the course of treatment but in most patients could be controlled well enough not to require discontinuation of the drug. Mitotane serum levels associated with the gastrointestinal side-effects were all above 5 mg 1'. CNS toxicity was seen especially with high mitotane serum levels, with cerebellar ataxia being the most common manifestation. Neuropsychological impairment was found during therapy. Deterioration varied individually from mild to severe, but always occurred when mitotane serum level exceeded 15 mg 1-. CNS toxicity reversed completely after drug withdrawal. A prolonged bleeding time was encountered in 90% of patients tested for platelet function (n = 10). Less frequent side-effects observed were rash (2-6 weeks after starting therapy) and a mild leucopenia.
Other therapy Twenty-one patients received one or two different chemotherapeutic regimens, apart from mitotane, at some time during their illness. Ten patients were treated early in the course of the disease and 11 during recurrence of the disease. The CAP regimen was administered to 12 patients, in two patients after unsuccessful mitotane treatment. Two patients achieved partial remissions lasting 18 and 23 months.
Seven patients received streptozotocin after tumour progression under mitotane, all without objective tumour response. Three patients received the cisplatin-etoposide regimen without tumour response.
Multivariate analysis of survival Using the Cox proportional hazards model, we evaluated the influence of the following variables on patient survival: (a) outcome of first surgery (no resection, subtotal or total resection); (b) mitotane treatment at some time during illness (no mitotane, low and high mitotane levels); (c) other chemotherapy at some time during illness (no, yes); (d) age at diagnosis (<40 years, >40 years); (e) year of diagnosis (<1980, > 1980); (f) sex (male, female); and (g) clinical features of hormonal dysfunction at presentation (no, yes). In all patients stepwise analysis of these variables showed that total resection at first surgery (P<0.001), mitotane treatment at some time during illness with high serum levels (P = 0.01) and female sex (P = 0.03) had independently a favourable influence on cumulative survival.
Stepwise analysis on the 49 patients who could not be operated upon (n = 12) or who had a subtotal tumour resection (n = 37) showed an independent, favourable influence on survival when mitotane treatment given at some time during illness resulted in high maintenance serum levels (P <0.001) and when treatment with other chemotherapy was undertaken (P = 0.005).
Discussion
The best chance of survival for a patient with adrenocortical carcinoma is when a complete tumour resection can be performed. Although excision of metastases could not cure our patients, we feel that debulking of tumour mass must be maximised since chemotherapy is considered to be more effective when tumour load is low (Harris & Mastrangelo, 1991) .
In our series, more than half of the patients with a seemingly complete tumour resection died of their disease within 5 years of surgery. It has been reported that local recurrence or metastases occur in 80% of the patients after radical surgery (Lipsett et al., 1963; Bertagna & Orth, 1981) . Spillage of tumour during operation may be the cause of tumour recurrence. However, in our series, rupture of the tumour capsule during surgery was not associated with shorter survival.
Our findings suggest a significant favourable effect of mitotane treatment on patient survival in adrenocortical carcinoma. Other authors have previously suggested a similar favourable effect (Hutter & Kayhoe, 1966b; Lubitz et al., 1973; Venkatesh et al., 1989) , but to our knowledge this has never been well documented. Moreover, in a large retrospective study Luton et al. (1990) could not find an independent beneficial effect resulting from mitotane therapy. Apart from the effectiveness of mitotane treatment, there are no major differences between our study and that of Luton et al. The discrepancy in findings between the two studies may lie in the different dosages of the drug used (or serum concentrations reached), as was suggested by van Slooten et al. in 1984 (Haak et al., 1990 . In the present study, an objective tumour response, according to the strict WHO criteria, was found in 15 of the 27 evaluable patients with levels above 14 mg 1'. Continuous serum levels under 14 mg l' resulted in no tumour response, and was tantamount to not giving mitotane at all.
The differential effect of sex on patient survival observed in our series is difficult to explain. The longer survival observed in patients who received other chemotherapy cannot be explained by objective tumour responses. It is possible that chemotherapy retarded tumour progression in our patients, resulting in a better survival. However, a bias may well have occurred in selecting patients for treatment with chemotherapy.
Despite all possible reservations against a retrospective study, we feel that our results prove the efficacy of mitotane in adrenocortical carcinoma. We have also clearly shown that a patient with adrenocortical carcinoma may only benefit from mitotane therapy when high serum levels of the drug can be reached.
An important reason for not reaching therapeutic levels may be undertreatment with steroids, resulting in signs and symptoms of adrenocortical insufficiency. Because of increased serum steroid-binding capacity during mitotane therapy, gluco-and mineralocorticoids must be supplied in higher than normal amounts (van Seters & Moolenaar, 1991) . A physician not aware of this will be more easily inclined to lower mitotane dosage or even to stop the drug. Of course, primary resistance of the tumour to mitotane and rapid progression of the disease may be a major factor in failure of the therapy.
Adjuvant mitotane therapy has been advocated after complete tumour resection (Venkatesh et al., 1989; Luton et al., 1990 ). In our study, patients who were treated adjuvantly with mitotane did not do better than those who did not receive it. On theoretical grounds, it is advisable to treat patients with an active drug when tumour load is low (Harris & Mastrangelo, 1991) . More than half of the patients develop recurrent disease after total tumour resection and must thus have residual tumour tissue. Since recurrence cannot be predicted, we feel that adjuvant therapy must be considered in all patients after total tumour resection. However, the majority of patients will not benefit from this treatment, for example when the carcinoma has been confidently completely resected, or when the carcinoma is unresponsive to mitotane. As the treatment is a burden to most patients, we would not advocate adjuvant mitotane treatment in patients with adrenocortical carcinoma after complete tumour resection.
We conclude that surgery offers the best hope for longterm survival for patients with adrenocortical carcinoma. Mitotane treatment for patients with inoperable, recurrent, and/or metastatic adrenocortical carcinoma is effective, provided that serum levels of the drug are maintained above 14mgl1'.
